Skip to main content
padlock icon - secure page this page is secure

Ketanserin stabilizes blood pressure in conscious spontaneously hypertensive rats

Buy Article:

$52.00 + tax (Refund Policy)

Summary

1. It has been demonstrated that blood pressure variability (BPV) is increased in hypertension and related to organ damage. It will be important to lower BPV in the treatment of hypertension. The present study was designed to investigate the effect of ketanserin, a 5-HT2A receptor antagonist with a weak α1-adrenoceptor blocking effect, on BPV in conscious spontaneously hypertensive rats (SHR).

2. It was found that ketanserin decreased blood pressure (BP) and BPV in SHR when administered intravenously (3 mg/kg, i.v.). Ketanserin decreased BPV, but not the BP level, when administered intracerebroventricularly (50 µg/rat, i.c.v.).

3. Prazosin, an α1-adrenoceptor antagonist, lowered BP but did not affect BPV when given either i.v. (0.5 mg/kg) or i.c.v. (30 ug/rat). Ritanserin (0.625 mg/kg, i.v.; 40 'ug/rat, i.c.v.), a 5-HT2A receptor antagonist, decreased BPV only when administered i.c.v. and did not modify the BP level.

4. Ketanserin enhanced arterial baroreflex function in SHR when given either i.v. or i.c.v.

5. The stabilizing effect of ketanserin on BP was persistent when administered intragastrically. This administration route is similar to oral administration clinically.

6. It is concluded that ketanserin is an antihypertensive agent with an effect of reducing BPV. This effect is mainly mediated by central 5-HT2A receptors and is probably attributable to the restoration of arterial baroreflex function.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: arterial baroreflex; blood pressure; blood pressure variability; hypertension; ketanserin; spontaneously hypertensive rat

Document Type: Research Article

Affiliations: Department of Pharmacology, Basic Medical College, Second Military Medical University, Shanghai, China

Publication date: March 1, 2003

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more